ENTAEnanta Pharmaceuticals, Inc.Healthcare · Biotechnologyas of 2026-09-25
Horizon

Issued 2026-09-25 at $11.88 · now $11.88 (2026-09-25, +0.0% since)

Based on its own history, a month from the 2026-09-25 close, ENTA has typically landed between $8.74 and $15.77 — a range of −26.4% to +32.8% from the issuance price $11.88.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

3,378 overlapping 1 month windows · 2013-03-21 – 2026-08-26 · basis climatology · forecast (batch). Base rate up 53.7% (90% CI 51.5–55.9%, ≈1,391 obs). Not a call on this stock — we have no evidence its odds differ.

The cone is anchored at the 2026-09-25 issuance close ($11.88) — the price the forecast resolves against on 2026-10-26, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where ENTA has typically landed a month from the 2026-09-25 close of $11.88 — the range is history, not a prediction.

$8.74worst · -26.4%$15.77best · +32.8%
  • now $11.88 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $11.57 (-2.6%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $9.97–$13.16
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $8.74–$15.77
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 3,378 windows spanning 2013-03-21 to 2026-09-25. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2022-04-25−44.0%−44.0%+0.0%
2024-12-09−43.1%−43.1%+0.0%
2022-04-27−42.3%−42.3%+1.4%
3 best
2013-11-08+90.6%−0.0%+90.6%
2013-11-13+82.3%−1.4%+87.1%
2013-11-11+81.3%+0.0%+90.7%

3,378 overlapping windows · 2013-03-21 – 2026-09-25 · not cherry-picked

Pending catalysts

  • December 2026 — Trial primary completion: Phase 2 primary completion: A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus (source, as of 2026-08-14)

Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~14 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
46%
+3.4%
n=13
Feb
62%
+7.3%
n=13
Mar
54%
−2.6%
n=13
Apr
50%
−0.4%
n=14
May
36%
−5.2%
n=14
Jun
57%
+5.2%
n=14
Jul
50%
−1.6%
n=14
Aug
57%
+2.1%
n=14
Sep
29%
−1.5%
n=14
Oct
38%
−2.0%
n=13
Nov
69%
+7.7%
n=13
Dec
69%
−0.2%
n=13

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$17$72025-12-05: 7 insider sales, $175K — Luly Jay R., Or Yat Sun, Kieffer Tara Lynn, Luu Brendan …2025-12-02: 2 insider sales, $8K — Trout Harry R. III, Capps Kathleen S.2025-12: 9 open-market sales, $183K↑ buys↓ salesdirector Luly Jay R. — Sale on 2025-12-05, filed same dayofficer Or Yat Sun — Sale on 2025-12-05, filed same dayofficer Kieffer Tara Lynn — Sale on 2025-12-05, filed same dayofficer Luu Brendan — Sale on 2025-12-05, filed same dayofficer Rottinghaus Scott T. — Sale on 2025-12-05, filed same dayofficer Trout Harry R. III — Sale on 2025-12-05, filed same dayofficer Capps Kathleen S. — Sale on 2025-12-05, filed same dayofficer Trout Harry R. III — Sale on 2025-12-02, filed 1 day after the tradeofficer Capps Kathleen S. — Sale on 2025-12-02, filed 1 day after the trade
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling
2025-12-05Luly Jay R.directorSale4,743 @ $14.23$67K−0.5% of holding−5.7%−30.4%858,026Form 4 · filed same day
2025-12-05Or Yat SunofficerSale2,390 @ $14.23$34K−0.6% of holding−5.7%−30.4%371,392Form 4 · filed same day
2025-12-05Kieffer Tara LynnofficerSale2,106 @ $14.23$30K−6.4% of holding−5.7%−30.4%30,620Form 4 · filed same day
2025-12-05Luu BrendanofficerSale1,394 @ $14.23$20K−3.5% of holding−5.7%−30.4%38,329Form 4 · filed same day
2025-12-05Rottinghaus Scott T.officerSale798 @ $14.23$11K−3.5% of holding−5.7%−30.4%21,792Form 4 · filed same day
2025-12-05Trout Harry R. IIIofficerSale542 @ $14.23$8K−3.2% of holding−5.7%−30.4%16,348Form 4 · filed same day
2025-12-05Capps Kathleen S.officerSale323 @ $14.23$5K−3.7% of holding−5.7%−30.4%8,377Form 4 · filed same day
2025-12-02Trout Harry R. IIIofficerSale380 @ $13.96$5K−2.2% of holding+2.8%−27.7%16,890Form 4 · filed 1 day after the trade
2025-12-02Capps Kathleen S.officerSale207 @ $13.96$3K−2.3% of holding+2.8%−27.7%8,700Form 4 · filed 1 day after the trade
2025-02-12Luly Jay R.directorPurchase45,000 @ $5.69$256K+5.6% of holding+20.2%+24.6%846,638Form 4 · filed same day
2024-12-06Luly Jay R.directorSale5,142 @ $8.06$41K−0.6% of holding−32.8%−0.2%801,638Form 4 · filed 4 days after the trade
2024-12-06Or Yat SunofficerSale2,591 @ $8.06$21K−0.7% of holding−32.8%−0.2%369,109Form 4 · filed 4 days after the trade
2024-12-06MELLETT PAUL JofficerSale2,591 @ $8.06$21K−2.7% of holding−32.8%−0.2%91,710Form 4 · filed 4 days after the trade
2024-12-06Luu BrendanofficerSale2,283 @ $8.06$18K−6.0% of holding−32.8%−0.2%36,047Form 4 · filed 4 days after the trade
2024-12-06Kieffer Tara LynnofficerSale2,283 @ $8.06$18K−7.2% of holding−32.8%−0.2%29,305Form 4 · filed 4 days after the trade
2024-12-06Rottinghaus Scott T.officerSale866 @ $8.06$7K−4.6% of holding−32.8%−0.2%17,918Form 4 · filed 4 days after the trade
2024-07-15Rottinghaus Scott T.officerSale5,375 @ $17.08$92K−19.8% of holding−20.3%−75.1%21,717Form 4 · filed same day
2024-07-12Rottinghaus Scott T.officerSale2,271 @ $15.04$34K−9.5% of holding−18.1%−73.1%21,717Form 4 · filed 3 days after the trade
2024-07-11Rottinghaus Scott T.officerSale4,299 @ $15.07$65K−15.2% of holding−11.9%−71.0%23,988Form 4 · filed 4 days after the trade
2024-06-17Kieffer Tara LynnofficerSale7,266 @ $12.33$90K−18.3% of holding+20.5%−59.3%32,341Form 4 · filed same day

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

85 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-08-08Rottinghaus Scott T.officerWithheld for tax1,46723,787Form 4
2026-03-11Peterson KristinedirectorAward / grant20,00020,000Form 4
2026-03-11Hata Yujiro SdirectorAward / grant20,00020,000Form 4
2026-03-11Russell LesleydirectorAward / grant20,00020,000Form 4
2026-03-11CARTER BRUCE L AdirectorAward / grant20,00020,000Form 4
2026-03-11FOLETTA MARK GdirectorAward / grant20,00020,000Form 4
2026-03-11Vance TerrydirectorAward / grant20,00020,000Form 4
2026-02-12Luly Jay R.directorWithheld for tax6,155871,871Form 4
2026-02-12Rottinghaus Scott T.officerWithheld for tax3,41325,254Form 4
2026-02-12Or Yat SunofficerWithheld for tax3,413374,854Form 4
2026-02-12Kieffer Tara LynnofficerWithheld for tax3,25733,925Form 4
2026-02-12Luu BrendanofficerWithheld for tax3,25741,634Form 4
2026-02-12Kowalsky Matthew PaulofficerWithheld for tax1,9023,591Form 4
2026-02-12Kieffer Tara LynnofficerAward / grant4,98737,182Form 4
2026-02-12Rottinghaus Scott T.officerAward / grant1,65023,442Form 4
2026-02-12Rottinghaus Scott T.officerAward / grant5,22528,667Form 4
2026-02-12Luu BrendanofficerAward / grant1,57539,904Form 4
2026-02-12Luu BrendanofficerAward / grant4,98744,891Form 4
2026-02-12Kowalsky Matthew PaulofficerAward / grant1,3181,318Form 4
2026-02-12Kowalsky Matthew PaulofficerAward / grant4,1755,493Form 4
2026-02-12Kieffer Tara LynnofficerAward / grant1,57532,195Form 4
2026-02-12Luly Jay R.directorAward / grant4,800862,826Form 4
2026-02-12Luly Jay R.directorAward / grant15,200878,026Form 4
2026-02-12Or Yat SunofficerAward / grant1,650373,042Form 4
2026-02-12Or Yat SunofficerAward / grant5,225378,267Form 4
2025-12-01Luly Jay R.directorWithheld for tax1,885862,769Form 4
2025-12-01Or Yat SunofficerWithheld for tax753373,782Form 4
2025-12-01Kieffer Tara LynnofficerWithheld for tax75332,726Form 4
2025-12-01Luu BrendanofficerWithheld for tax49839,723Form 4
2025-12-01Trout Harry R. IIIofficerWithheld for tax10517,270Form 4
2025-12-01Capps Kathleen S.officerWithheld for tax858,907Form 4
2025-11-25Capps Kathleen S.officerAward / grant3,1638,992Form 4
2025-11-25Kieffer Tara LynnofficerAward / grant100,000100,000Form 4
2025-11-25Trout Harry R. IIIofficerAward / grant12,92512,925Form 4
2025-11-25Trout Harry R. IIIofficerAward / grant6,46317,375Form 4
2025-11-25Rottinghaus Scott T.officerAward / grant110,000110,000Form 4
2025-11-25Or Yat SunofficerAward / grant110,000110,000Form 4
2025-11-25Luu BrendanofficerAward / grant90,00090,000Form 4
2025-11-25Luly Jay R.directorAward / grant310,000310,000Form 4
2025-11-25Kowalsky Matthew PaulofficerAward / grant90,00090,000Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.